Levofloxacin Mesylate Injection

Levofloxacin mesylate

This product is a light yellow-green clear liquid.

In order to reduce the emergence of drug-resistant bacteria and ensure the effectiveness of levofloxacin mesylate and other antimicrobial drugs, levofloxacin is only used to treat or prevent infections that have been proven or highly suspected to be caused by sensitive bacteria. The results of bacterial culture and drug sensitivity tests should be considered when selecting or modifying antimicrobial treatment regimens. If there are no data from these tests for reference, empirical treatment should be carried out based on local epidemiology and pathogen sensitivity. Before treatment, bacterial culture and drug sensitivity tests should be performed to isolate and identify the infecting pathogens and determine their sensitivity to levofloxacin mesylate. Levofloxacin can be used for treatment before the above test results are obtained, and the appropriate treatment method can be selected after the test results are obtained. As with other drugs in this class, when using levofloxacin mesylate for treatment, copper

Intravenous drip: 400 mg per day for adults, divided into 2 intravenous drips. For patients with severe infections and those with pathogens that are less sensitive to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 600 mg, divided into 2 intravenous drips.

1. Gastrointestinal reactions are relatively common and may manifest as symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating; 2. Central nervous system reactions may include dizziness, headache, drowsiness, or insomnia. 3. Allergic reactions: rash, skin itching, and occasionally exudative erythema multiforme and angioedema. A small number of patients have photosensitivity reactions. 4. Occasionally, the following may occur: (1) Epileptic seizures, mental disorders, irritability, confusion, hallucinations, and tremors; (2) interstitial nephritis manifestations such as hematuria, fever, and rash; (3) redness, itching, or phlebitis at the injection site; (4) crystalluria, which is more common when high doses are used; and (5) joint pain. 5. A small number of patients may experience transient liver function abnormalities, such as serum aminotransferases.

It is contraindicated for patients who are allergic to quinolones, pregnant and lactating women, and patients under 18 years of age.

Sealed storage

100ml:0.1g (based on levofloxacin)

China Resources Double-Crane Pharmaceutical Co., Ltd.

• Founded in:

  1997-05-16

• Address:

  No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing

• Tax NO.:

  91110000633796475U

• Registered Funds:

  1,038,836,522 yuan

• Website:

  Log in to view

• Email:

  Log in to view